Last updated: 31 January 2023 at 9:00pm EST

Steven Gelone Net Worth




The estimated Net Worth of Steven P. Gelone is at least $1.7 Million dollars as of 19 August 2020. Steven Gelone owns over 27,250 units of Nabriva Therapeutics Plc stock worth over $522,843 and over the last 8 years he sold NBRV stock worth over $0. In addition, he makes $1,178,280 as President and Chief Operating Officer at Nabriva Therapeutics Plc.

Steven Gelone NBRV stock SEC Form 4 insiders trading

Steven has made over 3 trades of the Nabriva Therapeutics Plc stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 27,250 units of NBRV stock worth $38,695 on 19 August 2020.

The largest trade he's ever made was exercising 27,250 units of Nabriva Therapeutics Plc stock on 19 August 2020 worth over $38,695. On average, Steven trades about 908 units every 11 days since 2017. As of 19 August 2020 he still owns at least 368,199 units of Nabriva Therapeutics Plc stock.

You can see the complete history of Steven Gelone stock trades at the bottom of the page.





Steven Gelone biography

Dr. Steven Gelone Pharm.D. is President, Chief Operating Officer of the Company. Dr. Gelone previously served as Nabriva Austria's chief development officer and head of business development from 2014 until the Redomiciliation, our chief development officer from the Redomiciliation until June 30, 2017 and our chief scientific officer from June 30, 2017 until July 24, 2018. Prior to joining Nabriva Austria, he served as head of clinical research and development at Spark Therapeutics, Inc. in 2014 and vice president of clinical and preclinical development at ViroPharma Incorporated from 2005 to 2014. Dr. Gelone also served as director of medical affairs at Vicuron Pharmaceuticals from 2002 to 2003 and director of clinical pharmacology and experimental medicine at GlaxoSmithKline Pharmaceuticals from 2000 to 2002. Dr. Gelone received his B.S. Pharm. and Pharm.D. from Temple University.

What is the salary of Steven Gelone?

As the President and Chief Operating Officer of Nabriva Therapeutics Plc, the total compensation of Steven Gelone at Nabriva Therapeutics Plc is $1,178,280. There are 2 executives at Nabriva Therapeutics Plc getting paid more, with Colin Broom having the highest compensation of $2,044,990.



How old is Steven Gelone?

Steven Gelone is 51, he's been the President and Chief Operating Officer of Nabriva Therapeutics Plc since 2018. There are 14 older and 3 younger executives at Nabriva Therapeutics Plc. The oldest executive at Nabriva Therapeutics Plc is George Talbot, 72, who is the Independent member of the Supervisory Board.

What's Steven Gelone's mailing address?

Steven's mailing address filed with the SEC is 414 COMMERCE DR., SUITE 120, FORT WASHINGTON, PA, 19034.

Insiders trading at Nabriva Therapeutics Plc

Over the last 8 years, insiders at Nabriva Therapeutics Plc have traded over $3,221,169 worth of Nabriva Therapeutics Plc stock and bought 436,925 units worth $1,215,585 . The most active insiders traders include Capital Viii, Llc Vivo, Bioventures Cayman Ltd Hbm, and Charles A Jr Rowland. On average, Nabriva Therapeutics Plc executives and independent directors trade stock every 33 days with the average trade being worth of $23,562. The most recent stock trade was executed by Daniel D Burgess on 2 August 2022, trading 11,341 units of NBRV stock currently worth $2,155.



What does Nabriva Therapeutics Plc do?

nabriva is a clinical-stage biopharmaceutical company engaged in the research and development of novel antibiotics to treat serious infections, with a focus on the pleuromutilin class of antibiotics. our goal is to become a fully integrated biopharmaceutical company focused on the research, development and commercialization of novel anti-infective products. nabriva was incorporated as a spin-off from sandoz gmbh antibiotics research institute (abri) in vienna, austria and commenced operations in february 2006. the new organization included small molecule assets, including pleuromutilin structure activity relationships (sar) knowledge and was focused on synthesis of pleuromutilins for systemic human use. following identification of our lead compound lefamulin and based on the clinical results of lefamulin for acute skin and skin structure infections. we believed that targeted in vitro spectrum of activity for the common pathogens causing community acquired bacterial pneumonia (cabp), wo



What does Nabriva Therapeutics Plc's logo look like?

Nabriva Therapeutics Plc logo

Complete history of Steven Gelone stock trades at Nabriva Therapeutics Plc

Date
#
Company
Insider
Trans.
Transaction
Shares Price per share Total value Shares after Source
19 Aug 2020 Steven P. Gelone
Director
Option 27,250 $165.00 $4,496,250
19 Aug 2020
368,199
19 Aug 2019 Steven P. Gelone
Director
Option 27,250 $552.50 $15,055,625
19 Aug 2019
55,776
23 Jun 2018 Steven P. Gelone
Director
Buy 10,000 $3.82 $38,200
23 Jun 2018
22,740


Nabriva Therapeutics Plc executives and stock owners

Nabriva Therapeutics Plc executives and other stock owners filed with the SEC include: